Literature DB >> 3015008

Enzymology and pathogenicity in mice of a herpes simplex virus type 1 mutant resistant to 2'-fluoro-2'-deoxy-1-beta-D-arabinofuranosyl-5-iodocytosine.

J Colacino, E Brownridge, N Greenberg, C Lopez.   

Abstract

The deoxypyrimidine nucleoside analog 2'-fluoro-2'-deoxy-1-beta-D-arabinofuranosyl-5-iodocytosine (FIAC) is a potent and selective inhibitor of herpes simplex virus type 1 in vitro (C. Lopez, K. A. Watanabe, and J. J. Fox, Antimicrob. Agents Chemother. 17:803-806, 1980). Isopycnographic analysis demonstrated that 1 microM FIAC inhibited herpes simplex virus DNA replication by more than 95% but inhibited cellular DNA replication by only 32%. Mutant herpes simplex virus type 1 selected resistant to FIAC displayed linked resistance to other nucleoside analogs, including arabinosylthymine and acyclovir. Lysates derived from Vero cells infected with FIAC-resistant virus showed markedly lower levels of thymidine kinase activity and were unable to phosphorylate selectively arabinosylthymine or FIAC, in contrast to lysates from cells infected with wild-type herpes simplex virus type 1. Finally, drug-resistant virus displayed a 6,000-fold decrease in pathogenicity when inoculated intraperitoneally into genetically susceptible A/J mice. These results indicate that resistance to deoxypyrimidine nucleoside analogs is due, at least in part, to alterations in viral thymidine kinase and is accompanied by decreased pathogenicity in vivo.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015008      PMCID: PMC284171          DOI: 10.1128/AAC.29.5.877

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Herpes simplex virus thymidine kinase expression in infection of the trigeminal ganglion.

Authors:  R B Tenser; M E Dunstan
Journal:  Virology       Date:  1979-12       Impact factor: 3.616

2.  Nucleosides. 110. Synthesis and antiherpes virus activity of some 2'-fluoro-2'-deoxyarabinofuranosylpyrimidine nucleosides.

Authors:  K A Watanabe; U Reichman; K Hirota; C Lopez; J J Fox
Journal:  J Med Chem       Date:  1979-01       Impact factor: 7.446

3.  Induction of both thymidine and deoxycytidine kinase activity by herpes viruses.

Authors:  A T Jamieson; G A Gentry; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1974-09       Impact factor: 3.891

4.  Pathogenicity of acyclovir-resistant herpes simplex virus type 1 from an immunodeficient child.

Authors:  C D Sibrack; L T Gutman; C M Wilfert; C McLaren; M H St Clair; P M Keller; D W Barry
Journal:  J Infect Dis       Date:  1982-11       Impact factor: 5.226

5.  In vitro metabolism of 1-beta-D-arabinofuranosylcytosine and 1-beta-2'-fluoroarabino-5-iodocytosine in normal and herpes simplex type 1 virus-infected cells.

Authors:  W Kreis; L Damin; J Colacino; C Lopez
Journal:  Biochem Pharmacol       Date:  1982-03-01       Impact factor: 5.858

6.  Metabolism of acyclovir in virus-infected and uninfected cells.

Authors:  P A Furman; P de Miranda; M H St Clair; G B Elion
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

7.  Pathogenicity in mice of strains of herpes simplex virus which are resistant to acyclovir in vitro and in vivo.

Authors:  H J Field; G Darby
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

8.  Development of clinical resistance to acyclovir in herpes simplex virus-infected mice receiving oral therapy.

Authors:  H J Field
Journal:  Antimicrob Agents Chemother       Date:  1982-05       Impact factor: 5.191

9.  Biotransformation and elimination of [2-14C]-1-(2-deoxy-2'-fluoro-beta-D -arabinofuranosyl)-5-iodocytosine in immunosuppressed patients with herpesvirus infections.

Authors:  A Feinberg; B Leyland-Jones; M P Fanucchi; C Hancock; J J Fox; K A Watanabe; P M Vidal; L Williams; C W Young; F S Philips
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

10.  Efficacy and selectivity of some nucleoside analogs as anti-human cytomegalovirus agents.

Authors:  J M Colacino; C Lopez
Journal:  Antimicrob Agents Chemother       Date:  1983-10       Impact factor: 5.191

View more
  1 in total

1.  Comparative activity of various compounds against clinical strains of herpes simplex virus.

Authors:  G Andrei; R Snoeck; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-02       Impact factor: 3.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.